A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability via Autoinjector Device versus Syringe in Patients with Multiple Sclerosis

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523757-33-00

Enrollment

120

Registered

2026-04-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple sclerosis

Brief summary

Incidence of treatment emergent adverse events (TEAE)

Detailed description

Incidence of TEAE

Interventions

DRUGUblituximab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of treatment emergent adverse events (TEAE)	—

Secondary

Measure	Time frame
Incidence of TEAE	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 4, 2026